Physician profile
Jeffrey Lynn Boone
NPI 1306010863
$286,771.52
in general payments reported to CMS, 2019-2025
35 companies · $94K in 2025
The $94K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75K · 2020: $13K · 2021: $20K · 2022: $47K · 2023: $29K · 2024: $9,185 · 2025: $94K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $76K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Food and Beverage: $5,452 · Education: $5,000 · Travel and Lodging: $3,419 · Honoraria: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $76,490.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,719.75 |
| Food and Beverage | $5,451.66 |
| Education | $5,000.00 |
| Travel and Lodging | $3,419.20 |
| Honoraria | $3,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $174,632.78 | 2019-2025 | Repatha, Repatha, Evenity |
| Heartflow, INC. | $82,262.20 | 2022-2025 | Ffrct |
| Kowa Pharmaceuticals America, INC. | $13,070.23 | 2019-2024 | Seglentis, Livalo |
| Novartis Pharmaceuticals Corporation | $12,308.53 | 2019-2025 | |
| Novo Nordisk INC | $688.77 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amarin Pharma, INC. | $463.82 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $431.59 | 2020-2025 | Farxiga, Wainua, Lokelma |
| Esperion Therapeutics, INC. | $424.40 | 2021-2025 | Nexletol |
| Cleerly, INC. | $346.70 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Boehringer Ingelheim Pharmaceuticals, INC. | $284.50 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $255.13 | 2022-2025 | |
| Medicure Pharma INC. | $234.63 | 2020-2022 | |
| Lilly USA, LLC | $158.89 | 2021-2025 | Zepbound, Mounjaro |
| Eisai INC. | $149.83 | 2021 | |
| Sanofi-Aventis U.S. LLC | $124.90 | 2019 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Boone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.